Frontiers in Immunology (Nov 2021)

Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

  • Joanna Balcerek,
  • Brian R. Shy,
  • Amy L. Putnam,
  • Lisa M. Masiello,
  • Angela Lares,
  • Florinna Dekovic,
  • Luis Acevedo,
  • Michael R. Lee,
  • Vinh Nguyen,
  • Weihong Liu,
  • Sreenivasan Paruthiyil,
  • Jingying Xu,
  • Ashley S. Leinbach,
  • Jeffrey A. Bluestone,
  • Jeffrey A. Bluestone,
  • Qizhi Tang,
  • Qizhi Tang,
  • Jonathan H. Esensten

Journal volume & issue
Vol. 12


Read online

We report on manufacturing outcomes for 41 autologous polyclonal regulatory T cell (PolyTreg) products for 7 different Phase 1 clinical trials over a 10-year period (2011-2020). Data on patient characteristics, manufacturing parameters, and manufacturing outcomes were collected from manufacturing batch records and entered into a secure database. Overall, 88% (36/41) of PolyTreg products met release criteria and 83% (34/41) of products were successfully infused into patients. Of the 7 not infused, 5 failed release criteria, and 2 were not infused because the patient became ineligible due to a change in clinical status. The median fold expansion over the 14-day manufacturing process was 434.8 -fold (range 29.8-2,232), resulting in a median post-expansion cell count of 1,841 x 106 (range 56.9-16,179 x 106). The main correlate of post-expansion cell number was starting cell number, which positively correlates with absolute circulating Treg cell count. Other parameters, including date of PolyTreg production, patient sex, and patient age did not significantly correlate with fold expansion of Treg during product manufacturing. In conclusion, PolyTreg manufacturing outcomes are consistent across trials and dates of production.